CNTX-6970 is under clinical development by Centrexion Therapeutics and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CNTX-6970’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNTX-6970 overview
CNTX-6970 is under development for the treatment of knee osteoarthritis pain. The drug candidate is administered orally in the form of tablet. It is a small molecule that acts by targeting the cytokine CCR2 (C-C Chemokine receptor type 2).
Centrexion Therapeutics overview
Centrexion Therapeutics is a clinical-stage pharmaceutical company develops drugs for pain. Its pipeline products include CNTX-4975, CNTX-6970, CNTX- 0290, CNTX-2022 and CNTX-6016 used for the treatment of osteoarthritis, neuropathic pain, dermatologic itch and pain. It also includes drug for diabetes pain, chemotherapy pain and others which works on pain signals. Centrexion Therapeutics develops non- addictive non-opioid drugs by merging combining translational science novel clinical trial strategies and big data analytics. It works in partnership with other companies in the field of artificial intelligence to advance its pipeline products. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of CNTX-6970’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
